Molecular-targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2-positive breast cancer. However, acquired resistance of various cancers to molecular-targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib-resistant cell lines from HER2-amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to over...
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of al...
Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a bi...
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients....
Molecular-targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are ev...
Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23...
Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth fa...
-amplified cell line BT-474. Lapatinib is also a molecular-targeted drug for HER2-positive breast ca...
Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to...
Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in bre...
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-posi...
Rationale: The characterization of new genetic alterations is essential to assign effective personal...
Introduction: Src tyrosine kinase overactivation has been correlated with a poor response to human e...
We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing...
Breast cancer is the most common female cancer diagnosed worldwide. In 2018 alone, there were over 2...
Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that l...
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of al...
Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a bi...
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients....
Molecular-targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are ev...
Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23...
Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth fa...
-amplified cell line BT-474. Lapatinib is also a molecular-targeted drug for HER2-positive breast ca...
Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to...
Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in bre...
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-posi...
Rationale: The characterization of new genetic alterations is essential to assign effective personal...
Introduction: Src tyrosine kinase overactivation has been correlated with a poor response to human e...
We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing...
Breast cancer is the most common female cancer diagnosed worldwide. In 2018 alone, there were over 2...
Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that l...
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of al...
Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a bi...
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients....